



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Placulumab

Cat. No.:	HY-P99775
CAS No.:	945781-29-3
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis ^[1] .						
In Vitro	Placulumab (0.01-1000 μ g/mL) has cytotoxicity to NS0 cells and peripheral blood mononuclear cells (PBMCs) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.						
In Vivo	<p>Placulumab (0.3, 1, 3 and 10 mg/kg; i.p.; twice weekly for 8 weeks) has effective anti-arthritis properties in Tg197 transgenic mouse model^[1].</p> <p>Pharmacokinetic (PK) parameters of Placulumab in cynomolgus macaques^[1]</p>						
	Route	Dose (mg/kg)	Exposure AUC _{0-336 h} (ng.h/mL)	Maximum concentration C _{max} (ng/mL)	Time of maximum concentration t _{max} (h)	Elimination half-life t _{1/2} (h)	Clearance C _L (mL/hr/kg)
	Intravenous injection (Males)	50	46000000	1320000	0.167	104	0.985
	Intravenous injection (Females)	50	43300000	1020000	0.211	97.4	1.06
	Route	Dose (mg/kg)	Exposure AUC _{0-336 h} (ng.h/mL)	Dose normalize exposure AUC _{0-336 h} (norm)	Maximum concentration C _{max} (ng/mL)	Time of maximum concentration t _{max} (h)	Elimination half-life t _{1/2} (h)
	Subcutaneous injection (Males)	0.5	676000	1350000	3190	50.0	120

Subcutaneous injection (Females)	0.5	445000	890000	2880	48.0	108
Subcutaneous injection (Males)	5	3940000	788000	22700	40.0	117
Subcutaneous injection (Females)	5	3840000	767000	23800	12.0	109
Subcutaneous injection (Males)	50	41600000	832000	272000	40.0	122
Subcutaneous injection (Females)	50	32300000	646000	212000	32.0	107

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gay RD, et al. Anti-TNF α domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs. 2010 Nov-Dec;2(6):625-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA